What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab
NEJM 354:980-982, Ozcan,C.,et al, 2006
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
NEJM 354:924-933,965, Yousry,T.A.,et al, 2006
IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006
Thrombolytic Therapy of Acute Ischemic Stroke During Pregnancy
Neurol 66:768-770, Murugappan,A.,et al, 2006
Clinicopath Conf, Diffuse Large B-Cell Lymphoma, EBV-Positive, with Immunosuppression
NEJM 354:1178-1184, Case 8-2006, 2006
Extent of Early Ischemic Changes on Computed Tomgraphy (CT) Before Thrombolysis
Stroke 37:973-978, Dzialowski,I.,et al, 2006
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
Imaging-Guided Acute Ischemic Stroke Therapy: From "Time is Brain" to "Physiology is Brain"
AJNR 27:728-735, Gonzalez,R.G., 2006
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis
Stroke 37:1205-1210, Montaner,J.,et al, 2006
Good Outcomes in Ischemic Stroke Patients treated With Intravenous Thrombolysis Despite Regressing Neurological Symptoms
Stroke 37:1332-1333, Baumann,C.R.,et al, 2006
Mycophenolate Mofetil in Dermatomyositis: Is It Safe?
Neurol 66:1245-1247, Rowin,J.,et al, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Antiplatelets, ACE Inhibitors, and Statins Combination Reduces Stroke Severity and Tissue At Risk
Neurol 66:1153-1158, Kumar,S.,et al, 2006
Is IV Tissue Plasminogen Activator Beneficial in Patients With Hyperdense Artery Sign?
Neurol 66:1171-1174, Qureshi,A.I.,et al, 2006
MATILDE Regimen Followed by Radiotherapy is an Active Strategy Against Primary CNS Lymphomas
Neurol 66:1435-1438, Ferreri,A.J.M.,et al, 2006
Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen Activator
Arch Neurol 63:661-664, Bambauer,K.Z.,et al, 2006
Transmission of Lymphocytic Choriomeningitis Virus by Organ Transplantation
NEJM 354:2235-2249, Fischer,S.A.,et al, 2006
Clinicopath Conf, Acute Ischemic Stroke
NEJM 354:2263-2271, Case 16:2006, 2006
Thrombolysis in Patients Older Than 80 Years With Acute Ischaemic Stroke: Canadian Alteplase for Stroke Effectiveness Study
JNNP 77:826-829,812, Sylaja, P.N.,et al, 2006
Safety of Mechanical Thrombectomy and Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke: Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) Trial, Part I
AJNR 27:1177-1182, W.S. Smith, for the Multi MERCI Investigators, 2006
Ischemic Strokes After Cardiac Catheterization
Arch Neurol 63:817-821, Khatri,P. &Kasner,S.E., 2006
Comparison of Tissue Plasminogen Activator Administration Management Between Telestroke Network Hospitals and Academic Stroke Centers
Stroke 37:1822-1827, Audebert,H.,et al, 2006
Thrombolysis (Tissue Plasminogen Activator) in Stroke: A Medicolegal Quagmire
Stroke 37:1917-1922, Weintraub,M.I., 2006
Door to Thrombolysis: ER Reorganization and Reduced Delays to Acute Stroke Treatment
Neurol 67:334-336, Lindsberg,P.J.,et al, 2006
Intravenous Recombinant Tissue Plasminogen Activator in a Pregnant Woman With Cardioembolic Stroke
Stroke 37:2168-2169, Wiese,K.M.,et al, 2006
Piracetam for Acute Ischemic Stroke
Stroke 37:2191-2192, Ricci,S.,et al, 2006
Neoplastic Meningitis
Neurologist 12:179-187, Chamberlain,M.C., 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
Improvement of Postherpetic Neuralgia After Treatment With Intravenous Acyclovir Followed by Oral Valacyclovir
Arch Neurol 63:940-942, Quan,D.,et al, 2006
Axonal Polyneuropathy After Acute Dimethylamine Borane Intoxication
Arch Neurol 63:1009-1012, Kuo,H.-C.,et al, 2006
Diffuse Cerebral Vasoconstriction (Call-Fleming Syndrome) and Stroke Associated with Antidepressants
Neurol 67:159-160, Noskin,O.,et al, 2006
Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006
Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006
Recurrent Ibuprofen-Induced Aseptic Meningitis: Evidence Against an Antigen-Specific Immune Response
Neurol 67:539-540, Periard,D.,et al, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Immune Reconstitution Inflammatory Syndrome in the CNS of HIV Infected Patients
Neurol 67:383-388, Venkataramana,A.,et al, 2006
Characteristics and Antecedents of Progressive Multifocal Leukoencephalopathy in an Insured Population
Neurol 67:884-886, Eng,P.M.,et al, 2006
Intra-Arterial Thrombolysis Is the Treatment of Choice for Basilar Thrombosis: Pro
Stroke 37:2436-2437,2440, Schellinger,P.D. &Hacke,W., 2006
Intra-Arterial Thrombolysis Is the Treatment of Choice for Basilar Thrombosis: Con
Stroke 37:2438-2439,2440, Ford,G.A., 2006
Tandem Internal Carotid Artery/Middle Cerebral Artery Occlusion: An Independent Predictor of Poor Outcome After Systemic Thrombolysis
Stroke 37:2301-2305, Rubiera,M.,et al, 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
High-Dose Atorvastatin After Stroke or Transient Ischemic Attack
NEJM 355:549-559,613, The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, 2006
Using the Baseline CT Scan to Select Acute Stroke Patients for IV-IA Therapy
AJNR 27:1612-1616, Hill,M.E.,et al, 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
The Neurologist 12:231-239, Kusner,L.,et al, 2006